The Induction of Metformin Inhibitory Effects on Tumor Cell Growth in Hypoxic Condition
-
Zohreh Safari
,
Reza Safaralizadeh
,
Mir Hadi Seyedzadeh
,
Ayla Valinezad Orang
,
Ahad Zare
,
Mohammad Ali Hosseinpour Feizi
,
Gholam Ali Kardar
Abstract
It is aimed to evaluate the actual anti-cancerous effects of metformin on cancer cells in hypoxic condition. Non-cancerous cells (HEK293) and cancer cells (MCF-7) were cultured in both hypoxia and normoxia conditions and treated with different concentrations of metformin. The proliferation, apoptosis, and necrosis rate were assessed using MTT test and Annexin V assay. The S6K1 phosphorylation was assessed using western blotting. Zymography was used to measure the activity of metalloproteinase-9 (MMP-9). Metformin treatment inhibited proliferation of cancer cells in the optimal concentration of 10 mM under hypoxia condition, while it showed no effects on non-cancerous cell viability. The statistical analysis of MTT assay indicated that the pro-apoptotic function of metformin for cancer cells under hypoxia condition compared to normoxia was significant with different metformin concentrations (p<0.01). However, the effect of metformin treatments for non-cancerous cells under hypoxia condition compared to normoxia was not significant. Western-blot analysis indicated a significant decrease in S6K1 phosphorylation in cancer cells under hypoxia condition (p<0.05). Nevertheless, there was no considerable difference between normoxia and hypoxia conditions in non-cancerous cells. MMP-9 zymography analysis revealed that the highest inhibition of MMP-9 activity was observed in hypoxia condition by 20mM of metformin concentration only in cancer cell. The results indicate that in hypoxia condition metformin exerts its anti-cancerous function by inhibiting proliferation and tumor progression and inducing cell apoptosis more effectively than normoxia condition. In line with cancer cell conditions, most importantly hypoxic condition, metformin can be considered as a potential anti-cancerous drug.
1. Kousidou OC, Roussidis AE, Theocharis AD, Karamanos NK. Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is associated with their invasive potential. Anticancer Res 2004; 24(6):4025-30.
2. Lorusso G, Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008; 130(6):1091-103.
3. Ward C, Langdon SP, Mullen P, Harris AL, Harrison DJ, Supuran CT, et al. New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev 2013; 39(2):171-9.
4. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia- inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92(12):5510-4.
5. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001; 93(4):309-14.
6. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59(22):5830-5.
7. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157(2):411-21.
8. Calzada MJ, Peso L. Hypoxia-inducible factors and cancer.Clin Transl Oncol 2007; 9(5):278-89.
9. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway inhuman prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60(6):1541–5.
10. Kaper F, Dornhoefer N, Giaccia AJ. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. cancer Res 2006; 66(3):1561–9.
11. Cho SJ, Chae MJ, Shin BK, Kim HK, Kim A. Akt- and MAPK-mediated activation and secretion of MMP-9 into stroma in breast cancer cells upon heregulin treatment. Mol Med Rep 2008; 1(1):83-8.
12. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3(10):721-32.
13. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F.Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010; 9(5):1092-9.
14. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006; 38(2):228-33.
15. Albanell J, Dalmases A, Rovira A, Rojo F. Mtor signaling in human cancer. Clin Transl Oncol 2007;9(8):484-93.
16. Belda-Iniesta C, Pernia O, Simo R. Metformin: a new option in cancer treatment. Clin Transl Oncol 2011;13(6):363-7.
17. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci 2012; 122(6):253-70.
18. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007;100(3):328-41.
19. Vázquez-Martín A, Oliveras-Ferraros C, Barco S, Martín- Castillo B, Menéndez J. mTOR inhibitors and the anti- diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®). Clin Transl Oncol 2009; 11(7):455-9.
20. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11(2):85-95.
21. Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH,Yeung SC. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 2011;15(4):825-36.
22. Hitron A, Adams V, Talbert J, Steinke D. The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol 2012;36(4):e243-50.
23. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta- analysis. Oncologist 2012; 17(6):813-22.
24. Rattan R, Ali Fehmi R, Munkarah A. Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol 2012; 2012:928127.
25. Oliveras-Ferraros C, Cufi S, Vazquez-Martin A, Torres- Garcia VZ, Del Barco S, Martin-Castillo B, et al. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFbeta-induced oncomiR miRNA-181a. Cell Cycle 2011; 10(7):1144-51.
26. Larsson O, Morita M, Topisirovic I, Alain T, Blouin MJ, Pollak M, et al. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci U S A 2012; 109(23):8977-82.
27. Hadad SM, Hardie DG, Appleyard V, Thompson AM.Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol 2014; 16(8):746-52.
28. Guillemin K, Krasnow MA. The hypoxic response:huffing and HIFing. Cell 1997; 89(1):9-12.
29. Dang CV. Links between metabolism and cancer. Genes Dev 2012; 26(9):877-90.
30. Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 2003;546(1):108-12.
31. Dewhirst MW, Secomb TW, Ong ET, Hsu R, Gross JF.Determination of local oxygen consumption rates in tumors. Cancer Res 1994; 54(13):3333-6.
32. Seyedzadeh MH, Safari Z, Zare A, Gholizadeh Navashenaq J, Razavi SA, Kardar GA, et al. Study of curcumin immunomodulatory effects on reactive astrocyte cell function. Int Immunopharmacol 2014;22(1):230-5.
33. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8(11):851-64.
34. Hsin CH, Wu BC, Chuang CY, Yang SF, Hsieh YH, Ho HY, et al. Selaginella tamariscina extract suppresses TPA-induced invasion and metastasis through inhibition of MMP-9 in human nasopharyngeal carcinoma HONE-1 cells. BMC Complement Altern Med 2013;13(234):1472-6882.
35. He J, Xu Q, Wang M, Li C, Qian X, Shi Z, et al. Oral Administration of Apigenin Inhibits Metastasis through AKT/P70S6K1/MMP-9 Pathway in Orthotopic Ovarian Tumor Model. Int J Mol Sci 2012; 13(6):7271-82.
| Files | ||
| Issue | Vol 14, No 6 (2015) | |
| Section | Original Article(s) | |
| Keywords | ||
| Breast cancer Hypoxia Metformin | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
